etiocholanolone has been researched along with Acute Disease in 11 studies
Etiocholanolone: The 5-beta-reduced isomer of ANDROSTERONE. Etiocholanolone is a major metabolite of TESTOSTERONE and ANDROSTENEDIONE in many mammalian species including humans. It is excreted in the URINE.
3alpha-hydroxy-5beta-androstan-17-one : An androstanoid that is 5beta-androstane substituted by an alpha-hydroxy group at position 3 and an oxo group at position 17. It is a metabolite of testosterone in mammals.
Acute Disease: Disease having a short and relatively severe course.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Istaroxime decreases PCWP, increases SBP, and decreases diastolic stiffness in patients with acute heart failure syndrome." | 9.14 | Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Trial in P ( Bianchetti, M; Blair, JE; Bubenek-Turconi, SI; Carminati, P; Ceracchi, M; Filippatos, GS; Gheorghiade, M; Grzybowski, J; Korewicki, J; Kremastinos, D; Macarie, C; Ruzyllo, W; Sabbah, HN; Shah, SJ; Valentini, G, 2009) |
| "We examined the hemodynamic, echocardiographic, and neurohormonal effects of intravenous istaroxime in patients hospitalized with heart failure (HF)." | 9.13 | Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure. ( Bianchetti, M; Blair, JE; Bubenek-Turconi, SI; Carminati, P; Ceracchi, M; Filippatos, GS; Gheorghiade, M; Korewicki, J; Kremastinos, D; Macarie, C; Ruzyllo, W; Sabbah, HN; Valentini, G, 2008) |
| "Sigma-Tau Ind Farm Riunite SpA and Debiopharm SA are developing istaroxime, the lead in a series of Na(+)/K(+)-ATPase inhibitors, for the potential treatment of cardiac failure." | 8.84 | Istaroxime, a novel luso-inotropic agent for the treatment of acute heart failure. ( Wehrens, XH, 2007) |
| "Istaroxime is a unique agent with both inotropic and lusitropic properties which is currently being studied for the treatment of AHFS." | 6.45 | Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na-K-ATPase inhibition: a new promising treatment for acute heart failure syndromes? ( Blair, JE; Filippatos, GS; Gheorghiade, M; Harinstein, ME; Khan, H; Metra, M; Porchet, H; Sabbah, HN; Valentini, G; Vogel, M, 2009) |
| "Istaroxime decreases PCWP, increases SBP, and decreases diastolic stiffness in patients with acute heart failure syndrome." | 5.14 | Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Trial in P ( Bianchetti, M; Blair, JE; Bubenek-Turconi, SI; Carminati, P; Ceracchi, M; Filippatos, GS; Gheorghiade, M; Grzybowski, J; Korewicki, J; Kremastinos, D; Macarie, C; Ruzyllo, W; Sabbah, HN; Shah, SJ; Valentini, G, 2009) |
| "We examined the hemodynamic, echocardiographic, and neurohormonal effects of intravenous istaroxime in patients hospitalized with heart failure (HF)." | 5.13 | Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure. ( Bianchetti, M; Blair, JE; Bubenek-Turconi, SI; Carminati, P; Ceracchi, M; Filippatos, GS; Gheorghiade, M; Korewicki, J; Kremastinos, D; Macarie, C; Ruzyllo, W; Sabbah, HN; Valentini, G, 2008) |
| "Sigma-Tau Ind Farm Riunite SpA and Debiopharm SA are developing istaroxime, the lead in a series of Na(+)/K(+)-ATPase inhibitors, for the potential treatment of cardiac failure." | 4.84 | Istaroxime, a novel luso-inotropic agent for the treatment of acute heart failure. ( Wehrens, XH, 2007) |
| "Diurnal variations of plasma testosterone and urinary excretion rates of testosterone-, androsterone-, aetiocholanolone-, and DHA-glucuronide, as well as DHA-sulphate were measured before and after selective Leydig-cell stimulation (with 3 X 5000 IU human gonadotrophin) in eight patients with alcoholic liver cirrhosis, ten with acute hepatitis and four with haemochromatosis." | 3.65 | [Androgen metabolism and Leydig-cell function in acute and chronic liver disease (author's transl)]. ( Gerdes, H; Littmann, KP; Martini, GA, 1975) |
| "Istaroxime is a unique agent with both inotropic and lusitropic properties which is currently being studied for the treatment of AHFS." | 2.45 | Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na-K-ATPase inhibition: a new promising treatment for acute heart failure syndromes? ( Blair, JE; Filippatos, GS; Gheorghiade, M; Harinstein, ME; Khan, H; Metra, M; Porchet, H; Sabbah, HN; Valentini, G; Vogel, M, 2009) |
| " An ideal inotropic drug should restore effective tissue perfusion by enhancing myocardial contractility without causing adverse effects." | 1.36 | Acute heart failure with low cardiac output: can we develop a short-term inotropic agent that does not increase adverse events? ( Campia, U; Gheorghiade, M; Nodari, S, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (27.27) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (54.55) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gheorghiade, M | 5 |
| Blair, JE | 3 |
| Filippatos, GS | 3 |
| Macarie, C | 2 |
| Ruzyllo, W | 2 |
| Korewicki, J | 2 |
| Bubenek-Turconi, SI | 2 |
| Ceracchi, M | 2 |
| Bianchetti, M | 2 |
| Carminati, P | 2 |
| Kremastinos, D | 2 |
| Valentini, G | 3 |
| Sabbah, HN | 4 |
| Dec, GW | 1 |
| Khan, H | 1 |
| Metra, M | 2 |
| Vogel, M | 1 |
| Harinstein, ME | 1 |
| Porchet, H | 1 |
| Shah, SJ | 1 |
| Grzybowski, J | 1 |
| Teerlink, JR | 1 |
| Zacà, V | 1 |
| Cotter, G | 1 |
| Cas, LD | 1 |
| Meyer, P | 1 |
| White, M | 1 |
| Keller, RF | 1 |
| Lerch, R | 1 |
| Hullin, R | 1 |
| Campia, U | 1 |
| Nodari, S | 1 |
| Wehrens, XH | 1 |
| Littmann, KP | 1 |
| Gerdes, H | 1 |
| Martini, GA | 1 |
| Gardner, FH | 1 |
| Juneja, HS | 1 |
| Goldberg, A | 1 |
| Moore, MR | 1 |
| Beattie, AD | 1 |
| Hall, PE | 1 |
| McCallum, J | 1 |
| Grant, JK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study to Assess the Hemodynamic Effects of Istaroxime, a Novel Lusinotropic Agent, in Patients Hospitalized With Worsening Heart Failure and a Reduced Left Ventricular Systolic Function[NCT00616161] | Phase 2 | 120 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| A Randomized, Double-blind, Placebo-controlled Escalating Dose Phase I Interaction Study to Evaluate the Pharmacokinetics, Tolerability and Pharmacodynamics of Three Dose Levels of Debio 0614 (Istaroxime) as a 24-hour Constant Rate IV Infusion in Combinat[NCT00869115] | Phase 1 | 0 participants (Actual) | Interventional | 2009-06-30 | Withdrawn (stopped due to The study was not started due to a re-evaluation of the istaroxime development program) | ||
| A Multicenter, Randomized, Double-blind, Placebo-controlled Staggered Dose-escalating Phase IIb Study of the Safety and Efficacy of Istaroxime Over 24 Hours at Three Doses in Acute Decompensated Heart Failure Patients (The IGNITE Trial)[NCT00838253] | Phase 2 | 0 participants (Actual) | Interventional | 2009-06-30 | Withdrawn (stopped due to The study was not started due to a re-evaluation of the istaroxime development program) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for etiocholanolone and Acute Disease
| Article | Year |
|---|---|
Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na-K-ATPase inhibition: a new promising treatment for acute heart failure syndromes?
Topics: Acute Disease; Animals; Cardiotonic Agents; Dobutamine; Etiocholanolone; Heart Failure; Hemodynamics | 2009 |
Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond.
Topics: Acute Disease; Cardiotonic Agents; Digoxin; Dobutamine; Etiocholanolone; Exercise Test; Heart Failur | 2009 |
[What is new in the medical management of acute heart failure?].
Topics: Acute Disease; Adenosine; Algorithms; Cardiotonic Agents; Diuretics; Drug Therapy, Combination; Etio | 2010 |
Istaroxime, a novel luso-inotropic agent for the treatment of acute heart failure.
Topics: Acute Disease; Animals; Cardiotonic Agents; Enzyme Inhibitors; Etiocholanolone; Heart Failure; Human | 2007 |
2 trials available for etiocholanolone and Acute Disease
5 other studies available for etiocholanolone and Acute Disease
| Article | Year |
|---|---|
Istaroxime in heart failure new hope or more hype.
Topics: Acute Disease; Cardiotonic Agents; Etiocholanolone; Heart Failure; Heart Rate; Humans; Stroke Volume | 2008 |
Acute heart failure with low cardiac output: can we develop a short-term inotropic agent that does not increase adverse events?
Topics: Acute Disease; Animals; Cardiac Output; Cardiotonic Agents; Clinical Trials as Topic; Digoxin; Dobut | 2010 |
[Androgen metabolism and Leydig-cell function in acute and chronic liver disease (author's transl)].
Topics: Acute Disease; Adult; Aged; Androgens; Androsterone; Chorionic Gonadotropin; Chronic Disease; Circad | 1975 |
Androstane therapy to treat aplastic anaemia in adults: an uncontrolled pilot study.
Topics: Acute Disease; Adolescent; Adult; Aged; Androstanes; Anemia, Aplastic; Chronic Disease; Colony-Formi | 1987 |
Excessive urinary excretion of certain porphyrinogenic steroids in human acute intermittent porphyria.
Topics: Acute Disease; Adult; Androsterone; Animals; Chromatography, Gas; Chromatography, Thin Layer; Dehydr | 1969 |